Expanded Access Program for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic, for the Treatment of Individual Patients With Serious or Immediately Life-threatening Infections Caused by Pseudomonas Aeruginosa

Trial Profile

Expanded Access Program for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic, for the Treatment of Individual Patients With Serious or Immediately Life-threatening Infections Caused by Pseudomonas Aeruginosa

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs AB PA01 (Primary) ; AB PA01 (Primary)
  • Indications Pseudomonal infections
  • Focus Expanded access; First in man; Therapeutic Use
  • Sponsors AmpliPhi Biosciences Corporation
  • Most Recent Events

    • 17 Jan 2018 New source identified and integrated (NCT03395743; ClinicalTrials.gov: US National Institutes of Health).
    • 03 Jan 2018 According to an AmpliPhi Biosciences Corporation media release, the company expects to review data from this program with the FDA in mid-2018.
    • 03 Jan 2018 Interim results (n=7) presented in an AmpliPhi Biosciences Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top